WHO ICTRP trial
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With…
EUCTR2017-002289-35-ES · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2017-002289-35-ES |
|---|---|
| Public title | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer |
| Scientific title | Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer |
| Primary sponsor | Seattle Genetics, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France;United States;Spain;Germany;Italy |
| Conditions | Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer MedDRA version: 20.0 Level: LLT Classification code 10072740 Term: Locally advanced breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and… |
| Interventions | Product Name: Ladiratuzumab vedotin Product Code: SGN-LIV1A Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: ladiratuzumab vedotin CAS Number: 1629760-29-7 Current Sponsor code: SGN-LIV1A Other descriptive… |
| Registration date | Feb 2, 2018 |
| Target size | 72 |
| Secondary IDs | SGNLVA-002 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: